Association of serum glycated albumin to haemoglobin A1C ratio with hepatic function tests in patients with chronic liver disease

2009 ◽  
Vol 46 (5) ◽  
pp. 368-372 ◽  
Author(s):  
Yukihiro Bando ◽  
Hideo Kanehara ◽  
Daisyu Toya ◽  
Nobuyoshi Tanaka ◽  
Soji Kasayama ◽  
...  
Keyword(s):  
Liver Disease ◽  
Chronic Liver Disease ◽  
Plasma Glucose ◽  
Glycated Albumin ◽  
Hepatic Function ◽  
Chronic Liver ◽  
Diabetic Patients ◽  
Haemoglobin A1c ◽  
Glucose Levels ◽  
The Mean

Background In patients with chronic liver disease (CLD), glycated haemoglobin (HbA1C) levels have been shown to be apparently lower than real values, whereas serum glycated albumin (GA) levels are apparently higher. The present study was aimed to examine whether both glycaemic indices are influenced by hepatic function. Methods Subjects consisted of 82 patients with CLD. Various indicators for hepatic function as well as HbA1C and GA were also measured. Estimated HbA1C values were calculated from the mean plasma glucose levels. Two hundred and two type 2 diabetic patients without CLD were studied as controls. Results Although GA was strongly correlated with HbA1C in patients with CLD as well as diabetic patients, GA levels in patients with CLD were relatively higher than those in diabetic patients. In patients with estimated HbA1C ≤5.8%, GA levels significantly increased but HbA1C levels decreased as a function of decreasing hepaplastin test (HPT). The ratio of GA/HbA1C (G/H ratio) increased as a function of decreasing HPT. In patients with estimated HbA1C >5.8%, in contrast, GA levels were independent of HPT levels. In the patients with CLD, GA and HbA1C were associated with mean plasma glucose levels and some indicators for hepatic function. The multivariate analysis revealed a significant association of G/H ratio with HPT, cholinesterase and direct bilirubin. The G/H ratio was not associated with the mean plasma glucose but with HPT and cholinesterase levels. Conclusions The G/H ratio correlates with hepatic function but not with plasma glucose levels. Therefore, CLD should be suspected for diabetic patients with an elevated G/H ratio.

Role of Flash Glucose Monitoring System in Diabetic Patients with Chronic Liver Disease

2021 ◽  
Vol 15 (8) ◽  
pp. 2096-2099
Author(s):  
Sadiq Hussain Malik ◽  
Sara Reza ◽  
Farheen Aslam ◽  
Saleha Zafar ◽  
Sadaf Shafiq
Keyword(s):  
Liver Disease ◽  
Chronic Liver Disease ◽  
Monitoring System ◽  
Glucose Monitoring ◽  
Chronic Liver ◽  
Diabetic Patients ◽  
Flash Glucose Monitoring ◽  
Glucose Levels ◽  
Freestyle Libre ◽  
Flash Glucose Monitoring System

Background: Diabetic patients show serious complications of chronic liver disease. The monitoring of glucose in diabetic patients with chronic liver disease is very challenging. Generally, the glycaemic control monitoring in chronic liver disease patients is the same as in a person who does not have any liver disease. Flash glucose monitoring system is a way to measure glucose levels of body without pricking the body. It is an innovative method of measuring glucose levels. A flash glucose monitor is a small sensor. This sensor is a small sticky chip and is attached on the skin of the arm. One side of the chip has a small needle that goes inside the skin. It records glucose levels throughout day and night continuously. Levels of glucose can be assessed whenever wanted. Materials and Methods: The study was conducted in the Medical Ward 1, Bahawal Victoria Hospital, Bahawalpur and the Department of Pathology, Quaid-e-Azam Medical College, Bahawalpur from 1st January 2018 to June 2020. Freestyle Libre Sensor flash glucose monitoring system (by CoolPlus Medical) was used to measure glucose of subcutaneous interstitial fluid. The disposable sensor was applied to the back of the arm for up to 14 days. Sensor is calibrated by the factory with no automatic alarms. Results: We noticed that the results of the patients who had co-existing disease of chronic hepatitis and diabetes mellitus had same results of glucose readings when measured by flash glucose monitoring system and by finger prick for glucose measurement by glucometer. Conclusion: Flash glucose monitoring system is way better than self monitoring blood glucose method by glucometer in diabetic patients with chronic liver disease. Keywords: Diabetes, glucose, monitoring, chronic liver disease, complications

Hepatic function and functional hepatic volumes correlate with the severity of chronic liver disease (CLD)

2000 ◽  
Vol 118 (4) ◽  
pp. A1448
Author(s):  
John C. Hoefs ◽  
Muhammad Y. Sheikh ◽  
Gary Kanel ◽  
Felix W. Wang ◽  
Norah Milne
Keyword(s):  
Liver Disease ◽  
Chronic Liver Disease ◽  
Hepatic Function ◽  
Chronic Liver

scholarly journals TOLAK UKUR FUNGSI HATI BERDASARKAN DERAJAT FIBROSIS PENYAKIT HATI KRONIS (Liver Function Parameters based on Degree of Liver Fibrosis in Chronic Liver Disease)

2018 ◽  
Vol 21 (1) ◽  
pp. 57
Author(s):  
Rahmafitria Rahmafitria ◽  
Mutmainnah Mutmainnah ◽  
Ibrahim Abdul Samad
Keyword(s):  
Liver Disease ◽  
Liver Fibrosis ◽  
Liver Function ◽  
Chronic Liver Disease ◽  
Total Bilirubin ◽  
Chronic Liver ◽  
Low Degree ◽  
Significant Difference ◽  
The Mean ◽  
High Degree

Evaluating the degree of liver fibrosis degree is invasive as well as uncomfortable, therefore, non invasive examinations such as liverfunction tests and elastography (Fibro Scan) as a predictor‘s device of liver fibrosis degree are necessary. The aim of this study was toknow the differences of liver function parameters based on the fibrosis degree in patients with chronic liver disease. This study was a crosssectional design using data from chronic liver disease patients treated at the Dr. Wahidin Sudirohusodo Hospital. The elasticity of the liverwas measured using a fibro scan device during June 2010–July 2011. The analysis was carried out by ANOVA test on various parametersof liver function particularly on the fibrosis degree in chronic liver disease. In this study PT, albumin, total bilirubin and platelet countshowed a significant difference of 0.019, 0.009, 0.017 and 0.000 respectively. The mean values of PT and total bilirubin were significantlyhigher in the high degree of fibrosis compared to those with medium and low degree of fibrosis in the chronic liver disease patients. Basedon this study, the mean albumin levels and platelet count were significantly lower in the high degree of fibrosis compared with the mediumand low degree of fibrosis, however, no significant differences in AST, ALT, APTT and GGT were found.

Immature Platelet Fraction in Patients with Chronic Liver Disease, A Marker for Evaluating Cirrhotic Changes.

2021 ◽  
Vol 17 (2) ◽  
pp. 174-179
Author(s):  
Muhammad Javaid Iqbal ◽  
Muhammad Usman ◽  
Mubarak Ali Anjum ◽  
Yasir Yaqoob ◽  
Ghulam Mujtaba Nasir ◽  
...  
Keyword(s):  
Platelet Count ◽  
Liver Disease ◽  
Chronic Liver Disease ◽  
White Blood Cells ◽  
Chronic Liver ◽  
Control Group ◽  
P Value ◽  
Master Program ◽  
Immature Platelet Fraction ◽  
The Mean

Objective: To evaluate the role of Immature platelet fraction in patients with chronic liver disease, a marker for evaluating cirrhotic changes. Methodology: This case control study was conducted at department of Pathology, Aziz Fatima Medical and Dental College, Faisalabad, over a period of Seven months from June 2020 to January 2021. A total of 126 participants were included in the study consisting of 63 patients with chronic liver disease in group A and 63 participants without any known disease in group B as control. The IPF master program in combination with XE-2100 multiparameter automatic hematology analyzer was used to measure the immature platelet fraction. Ethylene diamine tetraacetic acid was used to collect the blood sample for IPF measurement and was maintained till analysis on room temperature. Ten repeated analyses, immediately and after 24 hours were done for reproducibility of IPF%. Results: The mean age of liver disease patients was 52.35 ± 13.64 years and in control group the mean age was 51.62 ± 11.27 years. There was no significant (p-value > 0.05) difference between both groups based on age and gender. The hemoglobin level and red cell count was found to be significantly (p-value < 0.05) reduced in cases group. While white blood cells count was comparable in both groups. The mean platelet count was significantly (p-value < 0.05) less in cases group (163.5 ± 90.4 vs 233.4 ± 54.5 (x10*3/µl). The mean value of immature platelet fraction (IPF%) was significantly (p-value < 0.05) raised in cases group (5.62 ± 2.92 vs 3.06 ± 1.87). The multivariate discriminant analysis (MDA) score showed a significant (p-value < 0.05) association with chronic hepatis as compared to other liver related diseases. Conclusions: In chronic liver disease patients, there is an inverse relationship between platelet count and IPF% with decreased platelet count and increased IPF%. The proposed MDA function can be used to identify the cirrhotic changes in liver disease patients.

scholarly journals Nonalcoholic Fatty Liver Disease: A New Frontier for Hepatology in Bangladesh and a Call for Action to Combat

2017 ◽  
Vol 35 (4) ◽  
pp. 184-191
Author(s):  
Shahinul Alam ◽  
M Motahar Hossain ◽  
Golam Azam ◽  
Golam Mustafa ◽  
Mahbubul Alam ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Chronic Liver Disease ◽  
Fatty Liver Disease ◽  
Chronic Liver ◽  
Diabetic Patients ◽  
Socioeconomic Condition ◽  
Mortality And Morbidity ◽  
Nonalcoholic Fatty Liver

Nonalcoholic Fatty Liver Disease (NAFLD) is the condition where fat accumulates in liver without significant ingestion of alcohol. NAFLD has become one of the most common liver conditions throughout the world. At the dawn of the history of NAFLD it was thought that NAFLD is disease of obese individual but lean patients are increasingly detected to have NAFLD. It seems that insulin resistance is central to the pathogenesis of NAFLD. In addition, oxidative stress and cytokines are important contributing factors, resulting in steatosis and progressive liver damage in genetically susceptible individuals. NAFLD varies considerably by ethnic group and Bangladeshi ethnicity is an independent risk factor for NAFLD. Prevalence of NAFLD in general population of Bangladesh is 4 - 18.4 %, which jumps up to 49.8% in diabetic patients. With the changes in socioeconomic condition and life style, aetiology of chronic liver disease is drifting from infectious to noninfectious diseases and the contribution of NAFLD is progressively increasing. Hepatitis B and hepatitis C have been the leading causes of mortality and morbidity from chronic liver disease in Bangladesh. But with increase in awareness and mass vaccination against HBV, prevalence of both the diseases has been decreasing in the country. The most alarming feature is that there is a high prevalence of NASH among the NAFLD patients. NAFLD is emerging as the largest contributor of chronic liver disease in Bangladesh. This warrants the attention of health policy makers and clinicians to explore this frontier and combat it from right now.J Bangladesh Coll Phys Surg 2017; 35(4): 184-191

scholarly journals Colonoscopic band ligation for internal hemorrhoids - A tertiary care experience

2013 ◽  
Vol 04 (01) ◽  
pp. 006-009 ◽  
Author(s):  
Umesh Jalihal ◽  
Satya Prakash B S. ◽  
Avinash B. ◽  
Dheeraj Karanth
Keyword(s):  
Liver Disease ◽  
Chronic Liver Disease ◽  
Tertiary Care ◽  
Rubber Band Ligation ◽  
Rubber Band ◽  
Chronic Liver ◽  
Band Ligation ◽  
Care Experience ◽  
Internal Hemorrhoids ◽  
The Mean

ABSTRACT Background and objectives: Rubber band ligation (BL) is the most widely used technique for treatment of symptomatic internal haemorrhoids (IH) that are refractory to conservative treatment. The aim of this study is to assess the efficacy of colonoscopic BL as therapy for symptomatic IH. Methods: Patients seen at our center with symptomatic IH who underwent BL between January 2006 and December 2011 were included in this prospective study. The clinical and colonoscopic details were entered in uniform structured data forms. Results: Two hundred and eighteen consecutive patients with symptomatic IH were enrolled in the study. The presentations were rectal bleeding in 150 (69%) and prolapse in remaining 68 (31%) patients. Twenty-four patients (11%) had chronic liver disease (child B-C). Same operator treated all the patients. The severity of the IH was classified by using Goligher grading system. The mean age of patients was 48.3 + 15 years with range of 22 - 85 years. The mean follow up was 3months (range 1 month - 36 months). In 209 patients (96%) there was at least 1 grade reduction in hemorrhoids as well the symptoms were controlled. Two patients required surgery and another 7 patients required repeat session of banding. After banding session 32 (15%) patients had perianal pain and 13 (6%) had mild bleeding. Conclusions: Colonoscopic BL is a safe, and effective outpatient therapeutic procedure for symptomatic internal hemorrhoids. Furthermore, the BL is safe and effective in patients of coagulopathy associated with chronic liver disease. (J Dig Endosc 2013;4(1):6–9)

Quality of Life Score in Patients with Chronic Liver Disease using CLO Questionnaire

2021 ◽  
Vol 15 (11) ◽  
pp. 3467-3469
Author(s):  
Niaz Muhammad ◽  
Kashif Rafi ◽  
Hassan Nadeem ◽  
Muhammad Omer Farooq ◽  
Asmat Ullah ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Liver Disease ◽  
Chronic Liver Disease ◽  
Chronic Liver ◽  
Life Score ◽  
Class B ◽  
Pugh Class ◽  
The Mean ◽  
Class C

Aim: To determine the quality of life score in patients with chronic liver disease using CLO questionnaire. Study Design: Cross sectional study Place and Duration: Department of Gastroenterology, Shaikh Zayed Hospital Lahore during from 14-June-2016to 15-December-2016. Methodology: 180 consecutive patients of chronic liver disease were selected after taking Informed consent. The diagnosis was confirmed according to the data of clinical, biochemical examinations and the results of percutaneous liver biopsy data in some selected cases. All patients were subjected to exam, LFT's, RFT's and CBC, ultrasound abdomen, esophagogastroscopy which were enrolled in this study. Anti HCV, HBsAg, ferritin, Cerruloplasmin and Autoimmune profile, was done to establish the etiology. Severity of liver disease was estimated by Child-Pugh Score (Annexed). The chronic liver disease questionnaire (CLDQ) was applied as the instrument for measuring quality of life. Results: The mean age of the patients was 35.28±7.26 years. Majority of the patients were male as there frequency was 142 (78.9%). 127 (70.60 %) cases were found to be having a child pugh grade c severity of disease. Mean quality of life score was 16.3±5.88. Mean quality of life score in males was 16.21±6.21 while in female was 16.63±4.48. Similarly the mean quality of life score in child pugh class B was 13.77±4.58 and in child pugh class C was 17.35±6.05. Conclusion: It is concluded that the quality of life was bad in the patients who had child pugh class C as compared to those who had class B. Keywords: Quality of Life, Chronic Liver Disease, Cirrhosis

Evaluation of Metabolic Changes in HCV Diabetic Patients Treated With Direct Acting Antiviral Agents

QJM ◽  
2021 ◽  
Vol 114 (Supplement_1) ◽  
Author(s):  
Engy Yousry Elsayed ◽  
Hany Haroun Saad ◽  
Gina Gamal Naguib ◽  
Hazem Ibrahim Abouelela
Keyword(s):  
Uric Acid ◽  
Hepatitis C Virus ◽  
Liver Disease ◽  
Hepatitis C ◽  
Chronic Liver Disease ◽  
Serum Uric Acid ◽  
Metabolic Changes ◽  
Chronic Liver ◽  
Hcv Infection ◽  
Diabetic Patients

Abstract Background Viral hepatitis is a major public health problem in need of urgent response. The prevalence of hepatitis C virus (HCV) infection in Egypt is the highest in the world. Seroprevalence was modeled to 10.6% and viraemic prevalence to 7.3% in 2014. The association between hepatitis C virus (HCV) infection and diabetes has been widely postulated. Prospective studies have demonstrated a higher risk of developing type 2 diabetes mellitus (T2DM) and insulin resistance in the HCV population. Objective to evaluate metabolic changes in HCV-positive diabetic patients following combination therapy of hepatitis C, clarifying the role of DAAs in these changes. Patients and Methods This study was conducted in Ain Shams University Hospital outpatient clinics who attended from March to December 2018. our study included 70 patients, and were subdivided into the following two groups: Group I: Easy to treat group. Contains 35 diabetic patients with HCV related chronic liver disease treated with sofosbuvir, daclatasvir. Group II: Difficult to treat group. Contains 35 diabetic patients with HCV related chronic liver disease treated with sofosbuvir and daclatasvir and ribavirin. Results Treatment was considered successful when patients became non-viraemic as identified by negative HCV RNA serum PCR at 12 weeks from the end of the treatment regimens (SVR). It was found that diabetic patients treated with DAAs achieved reduction of HbA1C by mean of (0.724±0.3%). The mean increase of serum uric acid level was (0.607±0.4 mg/dL). There were increases in Cholesterol (by mean of 16.85±3.4), HDL (by mean of 5.34±2.1) and LDL (by mean of 13.91±4.2) as well as a decrease in TG (by mean of 13.56±5.1). Conclusion Our study concludes that HCV eradication in diabetic patients leads to various metabolic changes in the form of: Reduction of serum HbA1c level. Elevation of serum uric acid. Elevation of serum cholesterol, HDL, LDL as well as a decrease in TG. Further and larger studies are needed to evaluate the full magnitude of RBV effects on the patients’ metabolism.

scholarly journals Seroprevalence of hepatitis E virus (HEV) antibody and the possible association with chronic liver disease: a case-control study in Albania

2005 ◽  
Vol 134 (1) ◽  
pp. 95-101 ◽  
Author(s):  
L. A. KONDILI ◽  
P. CHIONNE ◽  
A. PORCARO ◽  
E. MADONNA ◽  
S. TAFFON ◽  
...  
Keyword(s):  
Liver Disease ◽  
Chronic Liver Disease ◽  
Case Control Study ◽  
Age Groups ◽  
Hepatitis E ◽  
Case Control ◽  
Chronic Liver ◽  
The Mean ◽  
End Stage ◽  
Control Study

SUMMARYA case-control study involving 109 in-patients with chronic liver disease and 190 in-patients with no apparent liver disease was conducted to evaluate the seroprevalence of anti-HEV antibodies and the possible association with chronic liver disease. Among cases, the anti-HEV prevalence was 36·6% which increased significantly by age; among controls, the prevalence was 12·1% (P<0·05) and was similar among age groups <60 years. Among cases, aged >50 years (OR 4·0, 95% CI 1·4–11) and the presence of end stage liver disease (ESLD) (OR 4·3, 95% CI 1·4–12·8) were associated independently with anti-HEV positivity. The mean optical density, determined by anti-HEV immunoenzymatic test, was significantly higher among patients with ESLD, compared to the other patients. These results indicate that there is a high seroprevalence of anti-HEV in patients with chronic liver disease and a possible association between HEV infection and/or anti-HEV production and advanced stage chronic liver disease.

Sign in / Sign up

Export Citation Format

Share Document